WASHINGTON (AP) — Federal health regulators on Friday declined to approve the psychedelic drug MDMA as a therapy for PTSD, a major setback for groups seeking a breakthrough decision in favor of using ...
A first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD was roundly criticized Tuesday — a potentially major setback to psychedelic advocates who hope to win a ...
When the Food and Drug Administration (FDA) declined to approve MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD) last year, the details of its objections were not ...
In September, the Food and Drug Administration released its recent complete response letter (CRL) to Lykos Therapeutics, denying approval for MDMA-assisted therapy for post-traumatic stress disorder.
An FDA advisory panel has resoundingly rejected the supplemental new drug application for the atypical antipsychotic brexpiprazole (Rexulti, Otsuka Pharmaceutical Co., Ltd.), in combination with the ...
On Friday, the FDA announced that it had agreed to allow a non-profit to research further the effects of treating people with posttraumatic stress disorder (PTSD) with ecstasy. According to a release ...
MDMA (3,4-methylenedioxymethamphetamine), known colloquially as Molly and Ecstasy, is a synthetic drug with effects similar to stimulants like methamphetamine. It was first synthesized in 1912 by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results